Equities Analysts Offer Predictions for BMRN FY2025 Earnings

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Investment analysts at Cantor Fitzgerald decreased their FY2025 earnings per share estimates for shares of BioMarin Pharmaceutical in a research report issued on Tuesday, October 28th. Cantor Fitzgerald analyst O. Brayer now forecasts that the biotechnology company will post earnings per share of $2.92 for the year, down from their previous forecast of $4.02. The consensus estimate for BioMarin Pharmaceutical’s current full-year earnings is $3.15 per share.

Other equities analysts have also issued reports about the company. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $66.00 target price on shares of BioMarin Pharmaceutical in a research report on Tuesday. Truist Financial decreased their price target on shares of BioMarin Pharmaceutical from $90.00 to $80.00 and set a “buy” rating for the company in a research note on Tuesday. UBS Group upped their price objective on shares of BioMarin Pharmaceutical from $113.00 to $114.00 and gave the stock a “buy” rating in a report on Tuesday, August 5th. Stifel Nicolaus dropped their price objective on shares of BioMarin Pharmaceutical from $91.00 to $73.00 and set a “buy” rating on the stock in a research note on Tuesday. Finally, JPMorgan Chase & Co. boosted their target price on shares of BioMarin Pharmaceutical from $116.00 to $119.00 and gave the stock an “overweight” rating in a research report on Thursday, October 9th. Sixteen investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $90.70.

BioMarin Pharmaceutical Stock Up 0.1%

BMRN stock opened at $51.91 on Thursday. The stock’s 50 day simple moving average is $54.88 and its 200 day simple moving average is $57.13. The company has a market cap of $9.97 billion, a P/E ratio of 19.52, a price-to-earnings-growth ratio of 0.68 and a beta of 0.33. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.60 and a current ratio of 4.83. BioMarin Pharmaceutical has a fifty-two week low of $51.10 and a fifty-two week high of $73.51.

Institutional Investors Weigh In On BioMarin Pharmaceutical

Several institutional investors and hedge funds have recently added to or reduced their stakes in BMRN. AQR Capital Management LLC boosted its stake in shares of BioMarin Pharmaceutical by 90.7% in the 2nd quarter. AQR Capital Management LLC now owns 5,580,573 shares of the biotechnology company’s stock worth $306,429,000 after buying an additional 2,654,768 shares during the last quarter. Nuveen LLC purchased a new stake in shares of BioMarin Pharmaceutical during the first quarter valued at approximately $184,475,000. Norges Bank bought a new stake in BioMarin Pharmaceutical during the second quarter worth $112,352,000. Viking Global Investors LP boosted its position in BioMarin Pharmaceutical by 13.8% in the second quarter. Viking Global Investors LP now owns 12,288,611 shares of the biotechnology company’s stock worth $675,505,000 after purchasing an additional 1,488,552 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its stake in BioMarin Pharmaceutical by 212.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,592,963 shares of the biotechnology company’s stock valued at $112,607,000 after purchasing an additional 1,083,512 shares during the period. Hedge funds and other institutional investors own 98.71% of the company’s stock.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.